SEC Company Response from Adams Respiratory Therapeutics, Inc. (CIK 0001319439) — Jul 18, 2005
Adams Respiratory Therapeutics, Inc. (CIK 0001319439)
Date: July 18, 2005 · CIK: 0001319439 · Accession: 0000950123-05-008593
AI Filing Summary & Sentiment
File numbers found in text: 333-123585
Letter
Re: Adams Respiratory Therapeutics, Inc. Registration Statement on Form S-1 (File Number 333-123585)
<PAGE>
MERRILL LYNCH, PIERCE, FENNER & MORGAN STANLEY & CO. INCORPORATED SMITH INCORPORATED 1585 BROADWAY 4 WORLD FINANCIAL CENTER NEW YORK, NY 10036 NEW YORK, NY 10080
July 18, 2005
VIA EDGAR
Securities and Exchange Commission Division of Corporate Finance 450 Fifth Street, N.W. Washington, D.C. 20549
Attention: Jeffrey P. Riedler - Legal Joseph Roesler - Accounting
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "Act"), on behalf of Merrill Lynch, Pierce, Fenner & Smith Incorporated, Morgan Stanley & Co. Incorporated, Deutsche Bank Securities Inc. and RBC Capital Markets Corporation, we hereby join Adams Respiratory Therapeutics, Inc. (the "Company") in requesting that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 2:00 p.m. Eastern Time on July 20, 2005, or as soon thereafter as possible.
In connection with this acceleration request and pursuant to Rule 460 under the Act, the following information is provided with respect to the distribution through 12:00 p.m. July 15, 2005 of the Preliminary Prospectus dated July 6, 2005:
<TABLE> <CAPTION> To Whom Distributed Number of Copies <S> <C> Underwriters 9,050 Dealers 0 Institutions 751 Individuals 12,614 Total 22,415 </TABLE>
This is to further advise you that the underwriters have complied and will continue to comply with SEC release No. 33-4968 and Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
<PAGE>
Securities and Exchange Commission -2- July 18, 2005
The Commission is further advised that the amount of compensation to be allowed or paid to the underwriters, to be disclosed in the Prospectus filed pursuant to Rule 424(b) under the Act, will not exceed an amount that has been cleared with the National Association of Securities Dealers, Inc.
Very truly yours,
MERRILL LYNCH, PIERCE, FENNER &
SMITH INCORPORATED
MORGAN STANLEY & CO. INCORPORATED
DEUTSCHE BANK SECURITIES INC.
RBC CAPITAL MARKETS CORPORATION
As Representatives of the several Underwriters
Show Raw Text
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.txt
<TEXT>
<PAGE>
MERRILL LYNCH, PIERCE, FENNER & MORGAN STANLEY & CO. INCORPORATED
SMITH INCORPORATED 1585 BROADWAY
4 WORLD FINANCIAL CENTER NEW YORK, NY 10036
NEW YORK, NY 10080
July 18, 2005
VIA EDGAR
Securities and Exchange Commission
Division of Corporate Finance
450 Fifth Street, N.W.
Washington, D.C. 20549
Attention: Jeffrey P. Riedler - Legal
Joseph Roesler - Accounting
Re: Adams Respiratory Therapeutics, Inc.
Registration Statement on Form S-1 (File Number 333-123585)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the
"Act"), on behalf of Merrill Lynch, Pierce, Fenner & Smith Incorporated, Morgan
Stanley & Co. Incorporated, Deutsche Bank Securities Inc. and RBC Capital
Markets Corporation, we hereby join Adams Respiratory Therapeutics, Inc. (the
"Company") in requesting that the effective date for the Registration Statement
referred to above be accelerated so that it will be declared effective at 2:00
p.m. Eastern Time on July 20, 2005, or as soon thereafter as possible.
In connection with this acceleration request and pursuant to Rule 460
under the Act, the following information is provided with respect to the
distribution through 12:00 p.m. July 15, 2005 of the Preliminary Prospectus
dated July 6, 2005:
<TABLE>
<CAPTION>
To Whom Distributed Number of Copies
<S> <C>
Underwriters 9,050
Dealers 0
Institutions 751
Individuals 12,614
Total 22,415
</TABLE>
This is to further advise you that the underwriters have complied and will
continue to comply with SEC release No. 33-4968 and Rule 15c2-8 under the
Securities Exchange Act of 1934, as amended.
<PAGE>
Securities and Exchange Commission -2- July 18, 2005
The Commission is further advised that the amount of compensation to be
allowed or paid to the underwriters, to be disclosed in the Prospectus filed
pursuant to Rule 424(b) under the Act, will not exceed an amount that has been
cleared with the National Association of Securities Dealers, Inc.
Very truly yours,
MERRILL LYNCH, PIERCE, FENNER &
SMITH INCORPORATED
MORGAN STANLEY & CO. INCORPORATED
DEUTSCHE BANK SECURITIES INC.
RBC CAPITAL MARKETS CORPORATION
As Representatives of the several Underwriters
By: MERRILL LYNCH, PIERCE, FENNER &
SMITH INCORPORATED
By: /s/ Samuel Thong
__________________________________
Name: Samuel Thong
Title: Director
By: MORGAN STANLEY & CO.
INCORPORATED
By: /s/ William L. Blais
__________________________________
Name: William L. Blais
Title: Managing Director
</TEXT>
</DOCUMENT>